Innovotech Inc. is developing products targeting biofilms, which are involved in 80% of human infections. Their technology platform includes diagnostic tests and treatments. Key opportunities are a biofilm susceptibility test approved in Canada and partnerships in healthcare and agriculture. Challenges include drug-resistant infections and a lack of approved anti-biofilm products. Innovotech aims to generate revenue from agricultural product approvals in 2010 and has $936,000 cash on hand to fund R&D towards advancing their product pipeline.

1. Innovotech Inc.Pursuing the Greatest Opportunityin Microbiology Since Penicillin On the Radar 1 December 2010

2. Forward Looking StatementsThis presentation contains forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Forward-looking statements may include words such as “expects”, “plans”, “will”, “believes”, “estimates”, “intends”, “may”, and other words of similar meaning and may relate to future financial performance, business strategies, or safety and efficacy of unapproved products.Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company’s reliance on a small number of customers including government organizations; the demand for new products and the impact of competitive products, service and pricing; availability and cost of raw materials; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defence; the Company’s exposure to lawsuits and other matters beyond the control of management.

3. OpportunityBiofilms

4. The natural state of bacteria

5. Plaque on teeth

6. Scum in shower

7. Cause 80% of human infections

8. Up to 1000x more resistant

9. No antibiotics, disinfectants or diagnostics approved for biofilms

10. Involved in most cases of MRSA and hospital-acquired infectionsOpportunityNew hospital superbugs proving resistant to antibioticsA new hospital superbug resistant to antibiotics has been brought into the country by patients returning home after surgery abroad. 13 Aug 2009Health Authorities Link 12 Deaths to Contaminated MeatTwelve deaths in Canada have now been linked to listeriosis, according to federal health officials who said Monday the deaths are among 26 confirmed cases of an outbreak across the country stemming from contaminated meat.Monday, Aug. 25, 2008Florida Orange Acres Fall as Farmers Cut Sick TreesOrange-crop acreage in Florida, the world's second-biggest producer, fell to a 24-year low as growers removed trees to slow the spread of disease affecting citrus crops, the U.S Department of Agriculture said.Thursday, September 23, 2010

11. Market Opportunity

12. Technology Platform DIAGNOSTIC Products:bioFILM PA™, Gram +/-ve testTREATMENT Products:Agress®, Sani-Lux™,AgreGuard™

13. Path to Market - HealthcareProduct - bioFILM PA™ (Susceptibility test)Validation

14. Clinical and health economic evaluation at University of Alberta Cystic Fibrosis clinic – 3 lives saved

15. Sick Kids (Toronto) trial showing different antibiotic selections 71% of time compared to traditional testing

16. Partner with established market players

17. LevPharm Ltd – Hospital distributor in Israel

18. Regulatory

19. Health Canada approval

20. Research Use Only provisions in USPath to Market - AgricultureProduct - Agress® (Seed treatment and Plant Spray)ValidationField trials – Streptomycin replacement Anti bacterial and anti-fungal activity Cost competitive and environmentally friendly Effective with existing productsPartner with established market playersSyngenta – largest seed treatment company in the worldRegulatory

21. Ready for EPA submissionCompetitionCompetition is from traditional methodsEstablished industries, little innovationDifficulties dealing with anti-microbial resistance

22. Environmental concerns

23. For bioFILM PA™

24. Empirical (educated guess)

25. For Agress®

26. StreptomycinMilestonesRevenue (000,000)- EPA Approval (Pulse, Horticulture, Potatoes)- EPA Application (Foliar)- EU Application (Pulse & Other)- Sick Kids trial complete- Hlth Canada approval for Gram +/-ve test- Marketing partnerEU Approval Gram +/-ve testEPA Application (Pulse, Horticulture, Potatoes)- PMRA Application (Pulse)FDA approval for Gram +/-ve test; initiate trial

27. History2003

28. 2004

29. 2006

30. 2007

31. 2010- Began trading on the Toronto Venture Exchange (TSX-V: IOT)- Completed Qualifying Transaction by acquiring University of Calgary technology- Amalgamation of Innovotech and MBEC BioProducts- Consolidation of operations in Edmonton- 21 employees in 3600 sq. ft. facility- Two products in advanced stages of development

32. People - BoardLorne Babiuk, PhDKerry Brown , CABruce Hirsche, LLMCorporate Secretary Wolfgang Muhs, PhDChairman of the BoardJohn Pinsent , CAGerard Tertzakian, PhDJames Timourian, PhDChief Financial OfficerVice President Research, University of Alberta. Former-Director, VIDO, University of Saskatchewan, a renowned vaccine development institute.

33. Former-Chairman, Foundation Equity Corporation, a successful technology venture capital firm.

34. Partner with Parlee McLaws LLP, specializing in intellectual property and technology development.

35. Executive in pharmaceutical manufacturing at Laporte PLC, Degussa GmbH and Rhodia Pharma Solutions. CEO of Raylo Chemicals.

36. Founding Partner, St Arnaud Pinsent, Steman a technology-focused chartered accounting firm. Former Director of Technology at Ernst and Young LLP.

37. Experience in the creation, management, and financing of knowledge-based companies. Former-Chair & CEO of Innovotech, Raylo Chemicals and Cytovax Biotechnologies.

38. Former CFO at Raylo Chemicals. Former Chairman of the Board at Ricon Resins Inc. Serial investor and board member in over 15 early-stage technology companies. People – Senior ManagementFormer senior manager at Glaxo SmithKline Inc, McKesson Canada and Canada Safeway Pharmacies Ltd with experience in operations and marketing spanning biotechnology, pharmaceutical manufacturing and distribution, and retail pharmacy.

39. World recognized biofilm expert. Experienced researcher and entrepreneur holding over 35 patents in medical and veterinary science and over 170 published papers. Inventor of the MBEC Assay™ and founder of MBEC Biofilm Technologies.

40. Former CFO at Raylo Chemicals. Former Chairman of the Board at Ricon Resins Inc. Serial investor and board member in over 15 early-stage technology companies.Ken Boutilier, MBAPresident and CEOMerle Olson, DVMResearch DirectorJim Timourian, PhDChief Financial Officer

41. Product PipelineOne platform technology – many productsPhase of DevelopmentMarket IntroductionRegulatoryResearch & DevelopmentbioFILM PA™Agress®Sani-Lux™Gram +/-ve testAgreGuard™Product*AgreGuard™ is a Silver technology for coating catheters; Sani Lux™ is a hard surface disinfectant

42. Financial HighlightsExpected revenue for 2010 - $1.5M

43. Low overheads

44. R&D expenditures - $550,000*

45. Burn rate - $82,000/month

46. Cash - $936,000*

47. Shares outstanding – 24M** As of September 30, 2010

48. SummaryInnovotech is a pioneer in the field of biofilm product developmentMedical, agricultural and industrial issues:World’s first biofilm susceptibility test

49. “Green”, and effective agricultural product

50. Strong pipeline based on a single technology platform

51. Revenue“All current microbiology may have to be reinvented to meet the needs of biofilm microbiology.”

52. Contact InformationKen Boutilier, President Innovotech Inc. ken.boutilier@innovotech.caPh: 780-448-0585 ext 221Fax: 780-424-0941